GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tien Liang BioTech Co Ltd (ROCO:4127) » Definitions » EV-to-EBIT

Tien Liang BioTech Co (ROCO:4127) EV-to-EBIT : 89.03 (As of May. 25, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Tien Liang BioTech Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tien Liang BioTech Co's Enterprise Value is NT$1,993.8 Mil. Tien Liang BioTech Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$22.4 Mil. Therefore, Tien Liang BioTech Co's EV-to-EBIT for today is 89.03.

The historical rank and industry rank for Tien Liang BioTech Co's EV-to-EBIT or its related term are showing as below:

ROCO:4127' s EV-to-EBIT Range Over the Past 10 Years
Min: -104.28   Med: 9.7   Max: 89.05
Current: 89.03

During the past 13 years, the highest EV-to-EBIT of Tien Liang BioTech Co was 89.05. The lowest was -104.28. And the median was 9.70.

ROCO:4127's EV-to-EBIT is ranked worse than
93.6% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs ROCO:4127: 89.03

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Tien Liang BioTech Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$1,266.3 Mil. Tien Liang BioTech Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$22.4 Mil. Tien Liang BioTech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.77%.


Tien Liang BioTech Co EV-to-EBIT Historical Data

The historical data trend for Tien Liang BioTech Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tien Liang BioTech Co EV-to-EBIT Chart

Tien Liang BioTech Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.41 -12.47 14.13 11.67 29.56

Tien Liang BioTech Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.34 18.32 20.99 29.56 56.54

Competitive Comparison of Tien Liang BioTech Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Tien Liang BioTech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tien Liang BioTech Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tien Liang BioTech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tien Liang BioTech Co's EV-to-EBIT falls into.



Tien Liang BioTech Co EV-to-EBIT Calculation

Tien Liang BioTech Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1993.847/22.394
=89.03

Tien Liang BioTech Co's current Enterprise Value is NT$1,993.8 Mil.
Tien Liang BioTech Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$22.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tien Liang BioTech Co  (ROCO:4127) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Tien Liang BioTech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=22.394/1266.263
=1.77 %

Tien Liang BioTech Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$1,266.3 Mil.
Tien Liang BioTech Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$22.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tien Liang BioTech Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Tien Liang BioTech Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Tien Liang BioTech Co (ROCO:4127) Business Description

Traded in Other Exchanges
N/A
Address
Datong Road, 9F, No. 147, Sec. 1, Xizhi District, New Taipei City, TWN
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis and hepatic diseases.

Tien Liang BioTech Co (ROCO:4127) Headlines

No Headlines